ArticleBioinformatics (Oxford, England)2026
ProDTI: prior-guided positive-unlabeled learning for robust drug-target interaction prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationAccurate Drug-Target Interaction (DTI) prediction is critical for drug discovery. While deep learning advances this field, the fundamental lack of verified negative interactions inevitably causes biased risk estimation. Although formulating DTI prediction as a Positive-Unlabeled (PU) learning problem is theoretically sound, directly applying PU learning to deep models suffers from early-stage optimization instability and decision boundary ambiguity.
resultsWe propose ProDTI, a prior-guided PU learning framework integrating domain knowledge into the PU objective. We construct a hybrid prior combining explicit biochemical similarities with implicit semantic representations from large-scale pre-trained models. This prior drives two synergistic mechanisms: soft-label distillation to stabilize the optimization trajectory, and hard-anchor regularization to explicitly penalize reliable negatives and sharpen decision boundaries. Evaluated on five benchmarks, ProDTI consistently outperforms state-of-the-art baselines, exhibiting superior robustness in challenging cold-start scenarios and providing a reliable tool for computational drug discovery. AVAILABILITY AND IMPLEMENTATION: Source code and data are available at https://github.com/WangYu-AI4SCI/ProDTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.